Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

Download Publication on intranasal sprays for respiratory viral infections
28 Jan 2022

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

1 Dec 2019

The Current State of Play in Connected Devices

Publications, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights, Device Innovations

Read More
1 Nov 2019

Exploring a Faster, More Cost-Effective Alternative to Generic Bioequivalence

Publications, Pharmaceutical, Product Solutions, Innovation & Insights

Read More
17 Jul 2019

New Tools to Advance CNS Drug Delivery

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 Jul 2019

Aptar Pharma discusses challenges and benefits of drug repurposing

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 23 24 25 26 27

Request Access

Close

Requesting access to Improving Intranasal Sprays for Respiratory Viral Infections.

  • This field is for validation purposes and should be left unchanged.
Back To Top